Share

February 2016; 3 (1) ArticleOpen Access

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values

Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, Johanna Breuer, Catharina C. Gross, Kerstin Göbel, David Brassat, Heinz Wiendl
First published January 27, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000195
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2509

Share

Article Information

vol. 3 no. 1 e195
DOI: 
https://doi.org/10.1212/NXI.0000000000000195
PubMed: 
26848486
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received July 29, 2015
  • Accepted in final form November 10, 2015
  • First Published January 27, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Nicholas Schwab, PhD*,
    2. Tilman Schneider-Hohendorf, PhD*,
    3. Béatrice Pignolet, PhD,
    4. Johanna Breuer, PhD,
    5. Catharina C. Gross, PhD,
    6. Kerstin Göbel, MD,
    7. David Brassat, MD, PhD and
    8. Heinz Wiendl, MD
  1. Nicholas Schwab, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Biogen, travel expenses, (2) Novartis, speaking honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Usage of L-selectin as predictive marker for PML.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) DFG CRC128 B1, starting 2012 (2) University M?nster, IMF, starting 2011

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Tilman Schneider-Hohendorf, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen, travel support for scientific conference attendance.

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) usage of L-selectin as predictive marker for the risk to develop PML (pantent nr.: EP 11 185 439 & EP 12 158 369)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Béatrice Pignolet, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Johanna Breuer, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Catharina C. Gross, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.

    Editorial Boards:

    1. Frontiers in Immunology, Review Editor, Since 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. German Research Foundation (DFG), GR3946/2-1, 01/2013-12/2015

    Research Support, Academic Entities:

    1. Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Kerstin Göbel, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. David Brassat, MD, PhD and
    8. Scientific Advisory Boards:

    1. Chugai pharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen idec, sanofi genzyme, teva, merck serono, bayer, almirall

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. French Ministry of Health 2007 PI, French multiple sclerosis Society 2005, 2006, 2007, 2008, European Union FP7 marie curie Action, 2008

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Heinz Wiendl, MD
    9. Scientific Advisory Boards:

    1. (1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva

    Editorial Boards:

    1. (1) Journal of Clinical Practice, Editorial Board member, since 2006 (2) Journal of Neuroinflammation, Editorial Board member, since 2007 (3) PLOS ONE, Editorial board member, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen Idec (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer Healthcare (2) Bayer Vital (3) Biogen Idec (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF), BD120300, Principal Investigator, 2012-2015 (2) German Ministry for Education and Research (BMBF), BD604262, Principal Investigator, 2013-2016 (3) Deutsche Forschungsgesellschaft (DFG), WI 1722/12-1, Principal Investigator, 2012-2015 (4) Deutsche Forschungsgesellschaft (DFG), WI 1722/13-1, Principal Investigator, 2012-2015 (5) European Union, BD604219, 2013-2015 (6) Deutsche Forschungsgesellschaft (DFG), SFB 1009 TP A3, Principal Investigator, 2012-2015 (6) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP A9, Principal Investigator, 2012-2015 (7) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP B1, Principal Investigator, 2012-2015 (8) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP Z2, Principal Investigator, 2012-2015 Else Kr?ner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, Merck Serono, Novartis, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, RE Children?s Foundation. (5) Novartis (6) Sanofi Aventis NovoNordisk)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (N.S., T.S.-H., J.B., C.C.G., K.G., H.W.), University of Münster, Germany; and Pole des Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., D.B.), CPTP INSERM UMR 1043 et Université de Toulouse, UPS, Toulouse, France. D.B. also represents the BioNAT Study Group.
  1. Correspondence to Prof. Wiendl: heinz.wiendl{at}ukmuenster.de or Dr. Schwab: nicholas.schwab{at}ukmuenster.de
View Full Text

Article usage

Article usage: January 2016 to August 2022

AbstractFullPdfSource
Jan 2016209371110Highwire
Feb 20161018813351Highwire
Feb 2016011061pmc
Mar 201630116784Highwire
Mar 2016010059pmc
Apr 201619113177Highwire
Apr 201607020pmc
May 20161738845Highwire
May 201604423pmc
Jun 20161387437Highwire
Jun 201603014pmc
Jul 2016846426Highwire
Jul 201602913pmc
Aug 20167911128Highwire
Aug 20160309pmc
Sep 2016353512Highwire
Sep 201604019pmc
Oct 2016515420Highwire
Oct 201602613pmc
Nov 2016715036Highwire
Nov 201602714pmc
Dec 2016743117Highwire
Dec 20160317pmc
Jan 2017704427Highwire
Jan 201703012pmc
Feb 2017464521Highwire
Feb 201703217pmc
Mar 2017464117Highwire
Mar 201702717pmc
Apr 201757289Highwire
Apr 2017101414pmc
May 2017523917Highwire
May 201751721pmc
Jun 201736416Highwire
Jun 2017101823pmc
Jul 201733347Highwire
Jul 201791618pmc
Aug 201720397Highwire
Aug 201772223pmc
Sep 201753284Highwire
Sep 2017719100pmc
Oct 2017652912Highwire
Oct 201732325pmc
Nov 201749368Highwire
Nov 201781623pmc
Dec 20175568Highwire
Jan 20186619Highwire
Feb 20189514Highwire
Mar 2018136110Highwire
Apr 20189976Highwire
Apr 2018122323pmc
May 2018141778Highwire
Jun 201851168Highwire
Jun 2018102124pmc
Jul 201851118Highwire
Aug 20184428Highwire
Aug 201841822pmc
Sep 201834411Highwire
Oct 2018156418Highwire
Nov 20181310612Highwire
Dec 201861588Highwire
Jan 20191817218Highwire
Feb 20192420710Highwire
Mar 2019109215Highwire
Apr 201997918Highwire
May 20191022016Highwire
Jun 2019612914Highwire
Jul 2019718916Highwire
Aug 20191113015Highwire
Sep 2019912324Highwire
Oct 2019514429Highwire
Nov 2019510932Highwire
Dec 2019813521Highwire
Jan 2020724319Highwire
Feb 202036620Highwire
Mar 202018521Highwire
Apr 202067910Highwire
May 2020211613Highwire
Jun 202024717Highwire
Jul 20202717Highwire
Aug 202035412Highwire
Sep 20201910525Highwire
Oct 20201212820Highwire
Nov 202075922Highwire
Dec 2020136010Highwire
Jan 202165420Highwire
Feb 202173220Highwire
Mar 2021116832Highwire
Apr 202113566Highwire
May 2021216018Highwire
Jun 202164111Highwire
Jul 2021104128Highwire
Aug 202194821Highwire
Sep 202194726Highwire
Oct 2021104126Highwire
Nov 202132839Highwire
Dec 2021186223Highwire
Jan 202245710Highwire
Feb 202296024Highwire
Mar 202277515Highwire
Apr 202257010Highwire
May 2022133817Highwire
Jun 20228647Highwire
Jul 202217755Highwire
Aug 20221210117Highwire

Cited By...

Letters: Rapid online correspondence

  • Re:Time to audit all reported PML cases
    • Nicholas Schwab, Assistant Professor, Department of Neurology, University of Muenster, Germany.
    • T. Schneider-Hohendorf; H. Wiendl;
    Submitted February 22, 2016
  • Time to audit all reported PML cases
    • Jagannadha Avasarala, Associate Professor of Neurology, Greenville Health System & U of South Carolina School of Medicine
    Submitted February 16, 2016
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Topics Discussed

Alert Me

Advertisement